A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration.

ABSTRACT: We conducted a genome-wide association study (GWAS) on the outcome of anti-VEGF treatment for exudative age-related macular degeneration (AMD) in a prospective cohort. Four hundred and sixty-one treatment-naïve AMD patients were recruited at 13 clinical centers and all patients were treated with 3 monthly injections of ranibizumab followed by pro re nata regimen treatment for one year. Genomic DNA was collected from all patients for a 2-stage GWAS on achieving dry macula after the initial treatment, the requirement for an additional treatment, and visual acuity changes during the 12-month observation period. In addition, we evaluated 9 single-nucleotide polymorphisms (SNPs) in 8 previously reported AMD-related genes for their associations with treatment outcome. The discovery stage with 25

SUBMITTER: Yamashiro K 

PROVIDER: S-EPMC5569099 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature